No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.

@article{Baldini1991NoCB,
  title={No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.},
  author={L. Baldini and Franca Radaelli and O Chiorboli and Stefano Fumagalli and Lilla Cro and Marco Segala and Bruno Mario Cesana and Elio E. Polli and Anna Teresa Maiolo},
  journal={Cancer},
  year={1991},
  volume={68 1},
  pages={62-7}
}
A vincristine, melphalan, cyclophosphamide, and prednisone (VMCP) multi-drug regimen was used in 85 previously untreated patients with multiple myeloma (MM) (symptomatic Durie Stages II and III) until they became refractory. The prognostic significance of various pretreatment characteristics was evaluated in terms of therapeutic response (according to Southwest Oncology Group [SWOG] and Chronic Leukemia-Myeloma Task Force [TF] criteria) and survival. Therapeutic responses, obtained in 31.2… CONTINUE READING

Similar Papers

Loading similar papers…